Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Veidekke ASA: To renovate Himmerfjärdsverket treatment plant for Syvab

Veidekke has signed an agreement with Syvab for comprehensive renovation and extensions to the Himmerfjärdsverket wastewater treatment plant in Grödinge, Sweden. The project has a potential order value of at least SEK 700 million, and work is planned to continue until 2025.“The renovation and extensions to Himmerfjärdsverket have long been under planning. As we are now finally ready to start implementation, we are very pleased and confident in the knowledge that we have Veidekke Entreprenad AB’s entire competence on hand in doing the job. This bodes well for a very good result,” says Carl-

Researchers uncover a new aspect of charge density modulations in high temperature superconductors

Researchers from Chalmers University of Technology and Politecnico di Milano have identified a crucial new aspect of charge density modulations in cuprate high critical temperature superconductors. They have identified a new electron wave which could help reveal some of the mysteries about superconducting materials. The findings are published in the journal Science. High critical temperature superconductors have a variable charge density, meaning that their electrical charge is unevenly distributed. This partly results from what are known as ‘charge density waves’, which were discovered

Camanio Care intends to divest its operations and subsidiaries to Brighter

Camanio Care AB (publ) ("Camanio Care") has signed a letter of intent with Brighter AB (publ) ("Brighter") regarding the divestment of all shares in Camanio Care's subsidiary Camanio AB, given that Camanio Care's all assets and liabilities are transferred to its subsidiary Camanio AB. Camanio Care's Board of Directors will engage an independent reviewer to evaluate the subsidiary before the Board decides whether they wish to proceed with the negotiations with Brighter. A prerequisite for the transaction is that Camanio Care’s shareholders decide in favour of the transaction at an

Brighter intends to acquire Camanio Care's subsidiary and sell its holding in Camanio Care.

Brighter AB (publ) ("Brighter") has signed a letter of intent with Camanio Care AB (publ) ("Camanio Care") regarding the acquisition of all shares in Camanio Care's subsidiary. A prerequisite for the acquisition is that Camanio Care's assets and liabilities have been transferred to Camanio Care's subsidiary. The intended acquisition of Camanio Care's subsidiary also requires that the planned acquisition is approved by Camanio Care at an Extraordinary General Meeting. Camanio Care's Board of Directors will also engage an independent reviewer to evaluate the subsidiary before the Board

BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer

Bergen, Norway, 8 September 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will present study updates from its Phase II clinical development programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, in non-small cell lung cancer (NSCLC) at the 2019 World Conference on Lung Cancer (WCLC) in Barcelona, Spain (07 - 10 September 2019).The two presentations will outline BerGenBio’s Phase II clinical trial (BGB008, NCT03184571) with bemcentinib and

Information update in the Quarterly report

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. In the quarterly report of Scandinavian Enviro Systems (“Enviro” or “The Company”) concerning Q2, 2019, which was published 23th August, extended information occurred in the English version compared to the Swedish due to a mistake in the translation process. As a result, Enviro has decided to publish an updated Swedish report, which now contains the same information as the English version.In the translated

Presentation of data where FG001 demonstrates dose-depended effectiveness in lightening up glioblastoma in a preclinical model

FluoGuide A/S’s ("FluoGuide", ticker FLUO) compound FG001 lights up the cancer and has in preclinically studies demonstrated potential to vastly improve the radicality of surgery in different types of cancer. Today data was presented at World Molecular Imaging Congress 2019 (WMIC) in Montreal, demonstrating dose-dependent FG001 effectiveness in lightening up glioblastoma in a preclinical model.Despite several decades of effort in improving the standard therapy of Glioblastoma (GBM), an aggressive form of cancer in the brain, the average life expectancy after a GBM diagnosis is only 14

Major League Baseball Players Alumni Association Brings Legends for Youth Baseball Coaches Clinic Series to Albertville, AL

Free coaches clinic to feature Matt Guerrier and other MLB AlumniColorado Springs, Colo. – Local coaches will have an opportunity to learn from former big league stars at the Major League Baseball Players Alumni Association (MLBPAA) Legends for Youth Coaches Clinic Series on Tuesday, September 10th, 2019. The free clinic features former Major League Baseball players who will instruct local coaches, parents, volunteers and students on proper fundamentals, drills and techniques of coaching and running a practice. Players attending* include 11-year MLB veteran pitcher Matt Guerrier, as well

Press release from the Annual General Meeting of Clas Ohlson AB (publ) on 7 September 2019

On Saturday 7 September 2019, Clas Ohlson AB held its Annual General Meeting (AGM) for the 2018/19 financial year in Leksand (in the company’s distribution centre in Insjön), whereby the following primary resolutions were adopted.For more detailed information on the content of the resolutions, please refer to the press release published on 5 August 2019 and the complete Notification of the AGM. The Notification of the AGM and the complete motions pertaining to the AGM resolutions listed below are available on Clas Ohlson AB’s website, https://about.clasohlson.com. Adoption of the

Presentation of data where use of FG001 demonstrates improved surgical outcome in metastatic pancreatic cancer compared to standard surgery using only white light

FluoGuide A/S’s ("FluoGuide", ticker FLUO) compound FG001 lights up the cancer and has in preclinically studies demonstrated potential to vastly improve the radicality of surgery in different types of cancer. Today data was presented at World Molecular Imaging Congress 2019 (WMIC) in Montreal, demonstrating how FG001 for in vivo fluorescent guidance improved surgical resection of metastatic pancreatic cancer in comparison with traditional white light surgery.Pancreatic cancer remains one of the deadliest cancers, and the one and five-year survival rates have been reported as 15% and 3% (

Panion’s board of directors evaluates development plan, terminates study before any enrolment, and withdraws INAD application to avoid substantial fees.

At a board meeting in Panion AB on September 6 2019, the development plan for Panion’s gene therapy product for treatment of drug-refractory epilepsy was discussed. The dog study at the veterinary clinic LIVS in New York is currently on hold. The board of directors decided to terminate the current study plan. Panion has had an excellent cooperation with the clinic and for clarity, no negative event has occurred in the planning of the study or with the product. As a consequence of the terminated study in dogs, the Board of directors decided to withdraw the open Investigational New Animal

Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study

Gothenburg, September 6, 2019 - Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, announced today that it has completed a 54-subject phase I dose-escalation study in the company’s VP01 project investigating the drug candidate C21, a first in class, oral, angiotensin II type 2 receptor (AT2R) agonist. The study established that 200 mg daily has a good safety profile and that it was the maximum tolerated dose. This dose will be used in the planned phase II studies in idiopathic pulmonary fibrosis (IPF) and diffuse

Telia Company comments media speculations

Telia Company notes speculations in media regarding the European Commission’s ongoing investigation into the acquisition of Bonnier Broadcasting. Telia Company has the following comments:The European Commission’s phase 2 investigation is still ongoing, and we are working closely and constructively with the Commission. We remain confident and will continue the dialogue, but we cannot comment the process any further as long as we haven’t been formally notified of a final decision.The Commission has until November 19, 2019, to decide on the merger.For more information, please contact our

Miris expands its distributor network with a new partner in Kuwait

The MedTech company Miris, best known by its Miris Human Milk Analyzer™ (Miris HMA™), has announced an exciting new partnership with Advanced Medical German Company in GCC and MENA Region.Advanced Medical German Co is the latest distributor to carry Miris medical equipment and products for human milk analysis. Advanced Medical German Company is one of the leading distributors in medical products and services, with a mission of improving health care services. Its corporate office is located in Kuwait and operates business in GCC and also in international market. Its business structure is

Mandatory notification of trade

On 6 September 2019, Flakk Invest AS purchased 100,000 shares of Hexagon Composites ASA at a price of NOK 26.38 per share. Flakk Invest AS is a company controlled by Mr. Knut Flakk, Chairman of Hexagon Composites ASA. The holding of Flakk Invest AS after the transaction is 1,300,000 shares, and the total holding of Mr. Knut Flakk and his close associates after the transaction is 29,384,969 shares. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

#19-1040 Delisting of certain derivatives from NGM

Certain derivatives will be delisted from NGM.For more details see attached files. For further information concerning this NGM notice please contact: Listing department on +46 8 566 390 20 or at listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

#19-1039 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Insr: Primary insider share purchase

Related parties to Insr's Board Member Øystein Engebretsen has today, September 6th, bought 75 000 shares in Insr Insurance Group ASA at a price of NOK 8.83 per share. After the transaction, Mr. Engebretsen and related parties hold a total of 3 681 000 shares. For further information, please contact:Anne B. Knudtzon,SVP Business Controlling & Investor RelationsT: +47 926 10 606E: anne.b.knudtzon@insr.io Partnership insurance made easy. Insr enables you to broaden your customer or member offering through white label and co-branding insurance solutions. We provide insurance risk

Notification of major holdings in the Company

TORM plc has been notified of the following transaction in TORM plc securities: TR-1: Standard form for notification of major holdings [][][][][][][] NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)[i] 1a. Identity of TORM plc the issuer or the underlying issuer of existing shares to which voting rights are attached[ii]: 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate) Non-UK

Yvonne Mårtensson leaves the board of SyntheticMR AB

Yvonne Mårtensson has today announced that she wishes to step down as chairman of the Board of SyntheticMR. The reason for this is different views on how the board work should be conducted. Yvonne leaving the board takes place with immediate effect. During the time until the General Meeting appoints a new board member, the Board has elected Johan Sedihn as chairman. For additional information, please contact Ulrik Harrysson, CEO  SyntheticMR AB, +46 70 529 29 87.  This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse

SDLP - Suspension of Trading from the NYSE and Commencement of NYSE Delisting Procedures

London, United Kingdom, September 6, 2019 - Seadrill Partners LLC (NYSE: SDLP) (“Seadrill Partners” or the “Company”) has received notification from The New York Stock Exchange (the “NYSE”) that trading in the Company’s common units has been suspended and proceedings to delist the Company’s common units have commenced. The NYSE reached its decision due to the Company’s low market capitalization pursuant to Section 802.01B of the NYSE’s Listed Company Manual. The Company expects its common units to trade in the over the counter (“OTC”) market beginning on September 6, 2019 under the

IFS EXPANDS REGIONAL HQ IN SINGAPORE

GLOBAL EBITA DOUBLES IN H1 2019 & YEAR-END REVENUE GUIDANCE UP 21% TO 711M USDNew IFS management’s partner-focus strategy and “Challenger” value proposition accelerates IFS performance within a year, outperforming the global plan to be a 1Bn USD revenue company in 3 years.  Singapore’s IFS regional headquarter poised to achieve highest growth, relocating to Suntec Tower 2 with 25% headcount increment across APJMEA and new senior management appointments to capture market share in Singapore. On 6 March 2019, IFS moved to Suntec Tower 2 (#27-02) on 9 Temasek Boulevard after a record-

Inhalation Sciences changes CEO

Inhalation Sciences (ISAB), which develops and commercializes world-leading instruments for inhalation research, today announces that it intends to replace its CEO. The company intends to announce the name of its new CEO next week. For the present Lena Heffler will continue as the company’s CEO.Inhalation Sciences (ISAB) develops an advanced aerosol R&D system that minimizes errors, reduces risk and speeds up the development of inhalable drugs. The company is in the early commercialization phase, and has recently announced its intention to validate the technology to meet growing market

There are no items matching the current filter
There are no more items matching the current filter
Back to top